CTLA-4-Ig regulates tryptophan catabolism in vivo

Nature Immunology

Volumn 3, Issue 11, 2002, Pages 1097-1101

  Grohmann, Ursula ^a   Orabona, Ciriana ^a   Fallarino, Francesca ^a   Vacca, Carmine ^a   Calcinaro, Filippo ^a   Falorni, Alberto ^a   Candeloro, Paola ^a   Belladonna, Maria L ^a   Bianchi, Roberta ^a   Fioretti, Maria C ^a   Puccetti, Paolo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HYBRID PROTEIN; IMMUNOGLOBULIN; LIGAND; LYMPHOCYTE ANTIGEN RECEPTOR; STREPTOZOCIN; TRYPTOPHAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; GRAFT SURVIVAL; HOST; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; MALE; MODULATION; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, DIFFERENTIATION; CELLS, CULTURED; DENDRITIC CELLS; DIABETES MELLITUS, EXPERIMENTAL; DNA-BINDING PROTEINS; ENZYME ACTIVATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; GRAFT ENHANCEMENT, IMMUNOLOGIC; GRAFT SURVIVAL; IMIDAZOLES; IMMUNE TOLERANCE; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; INTERFERON TYPE II; ISLETS OF LANGERHANS TRANSPLANTATION; ISOANTIGENS; KYNURENINE; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDES; PYRIDINES; RECOMBINANT FUSION PROTEINS; STAT1 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TRANSPLANTATION, HOMOLOGOUS; TRYPTOPHAN; TRYPTOPHAN OXYGENASE;

EID: 0036852170     PISSN: 15292908     EISSN: None     Source Type: Journal    
DOI: 10.1038/ni846     Document Type: Article

References (53)

1. Thompson, C. B. and Allison, J. P. The emerging role of CTLA-4 as an immune attenuator. Immunity 7, 445-450 (1997).
2. Oosterwegel, M. A., Greenwald, R. J., Mandelbrot, D. A., Lorsbach, R. B. and Sharpe, A. H. CTLA-4 and T cell activation. Curr. Opin. Immunol. 11, 294-300 (1999).
3. Salomon, B. and Bluestone, J. A. Complexities of CD28/B7:CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19, 225-252 (2001).
4. Tivol, E. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3, 541-547 (1995).
5. Waterhouse, P. et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270, 985-988 (1995).
6. Perez, V. L. et al. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6, 411-417 (1997).
7. Leach, D. R., Krummel, M. F. and Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734-1736 (1996).
8. Luhder, F., Hoglund, P., Allison, J. P., Benoist, C. and Mathis, D. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J. Exp. Med. 187, 427-432 (1998).
9. Karandikar, N. J., Vanderlugt, C. L., Walunas, T. L., Miller, S. D. and Bluestone, J. A. CTLA-4: a negative regulator of autoimmune disease. J. Exp. Med. 184, 783-788 (1996).
10. Lin, H. et al. Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28. J. Exp. Med. 188, 199-204 (1998).
11. Fallarino, F., Fields, P. E. and Gajewski, T. F. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. J. Exp. Med. 188, 205-210 (1998).
12. Fecteau, S. et al. CTLA-4 up-regulation plays a role in tolerance mediated by CD45. Nature Immunol. 2, 58-63 (2001).
13. Turka, L. A. et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc. Natl. Acad. Sci. USA 89, 11102-11105 (1992).
14. Li, W. et al. Costimulation blockade promotes the apoptotic death of graft-infiltrating T cells and prolongs survival of hepatic allografts from FLT3L-treated donors. Transplantation 78, 1423-1432 (2001).
15. Lenschow, D. J. et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 257, 789-792 (1992).
16. Judge, T. A. et al. The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. J. Immunol. 162, 1947-1951 (1999).
17. Zheng, X. X. et al. The role of donor and recipient B7-1 (CD80) in allograft rejection. J. Immunol. 159, 1169-1173 (1997).
18. Suvas, S., Singh, V., Sahdev, S., Vohra, H. and Agrewala, J. N. Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphomas. J. Biol. Chem. 277, 7766-7775 (2002).
19. Munn, D. H. et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281, 1191-1193 (1998).
20. Munn, D. H. et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189, 1363-1372 (1999).
21. Mellor, A. L. et al. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nature Immunol. 2, 64-68 (2001).
22. + subset. J. Immunol. 165, 1357-1363 (2000).
23. + dendritic cells expressing indoleamine 2,3-dioxygenase. J. Immunol. 167, 708-714 (2001).
24. + dendritic cells. Int. Immunol. 14, 65-68 (2002).
25. Tran, H. M. et al. Distinct mechanisms for the induction and maintenance of allograft tolerance with CTLA-4-Fc treatment. J. Immunol. 159, 2232-2239 (1997).
26. Taylor, M. W. and Feng G. S. Relationship between interferon-γ, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 5, 2516-2522 (1991).
27. Gajewski, T. F., Fallarino, F., Uyttenhove, C. and Boon, T. Tumor rejection requires a CTLA-4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J. Immunol. 156, 2909-2917 (1996)
28. Hassanain, H. H., Chon, S. Y. and Gupta S. L. Differential regulation of human indoleamine 2,3-dioxygenase gene expression by interferons-γ and -α. Analysis of the regulatory region of the gene and identification of an interferon-γ-inducible DNA-binding factor. J. Biol. Chem. 268, 5077-5084 (1993).
29. Babcock T. A. and Carlin, J. M. Transcriptional activation of indoleamine dioxygenase by interleukin I and tumor necrosis factor α in interferon-treated epithelial cells. Cytokine 12, 588-594 (2000).
30. Grohmann, U. and Puccetti, P. The immunosuppressive activity of proinflammatory cytokines in experimental models: potential for therapeutic intervention in autoimmunity. Curr. Drug Targets Inflamm. Aller. 1, 77-87 (2002).
31. Sica, A. et al. Interaction of NF-κB and NFAT with the interferon-γ promoter. J. Biol. Chem. 272, 30412-30420 (1997).
32. Zhang, S. and Kaplan, M. H. The p38 mitogen-activated protein kinase is required for IL-12-induced IFN-γ expression. J. Immunol. 165, 1374-1380 (2000).
33. Saccani, S., Pantano, S. and Natoli, G. p38-dependent marking of inflammatory genes for increased NF-κB recruitment. Nature Immunol. 3, 69-75 (2002).
34. Greenwald, R. J., Boussiotis, V. A., Lorsbach, R. B., Abbas, A. K. and Sharpe, A. H. CTLA-4 regulates induction of anergy in vivo. Immunity 14, 145-155 (2001).
35. Hall, B. M., Jelbart, M. E., Gurley, K. E. and Dorsch, S. E. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine: mediation of specific suppression by T helper/inducer cells. J. Exp. Med. 162, 1683-1694 (1985).
36. Qin, S. et al. "Infectious" transplantation tolerance. Science 259, 975-977 (1993).
37. Grohmann, U. et al. CD40 ligation ablates the tolerogenic potential of lymphoid dendritic cells. J. Immunol. 166, 277-283 (2001).
38. Mellor, A. L. and Munn, D. H. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol. Today 20, 469-473 (1999).
39. Fallarino, F. et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 9, 1069-1077 (2002).
40. Latour, S. et al. Bidirectional negative regulation of human T and dendritic cells by CD47 and its cognate receptor signal-regulator protein-α: down-regulation of IL-12 responsiveness and inhibition of dendritic cell activation. J. Immunol. 167, 2547-2554 (2001).
41. Suzuki, I. and Fink P. J. Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand. J. Exp. Med. 187, 123-128 (1998).
42. van Kooten, C. and Banchereau, J. Functions of CD40 on B cells, dendritic cells and other cells. Curr. Opin. Immunol. 9, 330-337 (1997).
43. Nathan, C. and Muller, W. A. Putting the brakes on innate immunity: a regulatory role for CD200? Nature Immunol. 2, 17-19 (2001).
44. Cowan, C. A. and Henkemeyer, M. Ephrins in reverse, park and drive. Trends Cell. Biol. 12, 339-346 (2002).
45. Kacktein, H., Morelli, A. E. and Thomson, A. W. Designer dendritic cells for tolerance induction: guided not misguided missiles. Trends Immunol. 22, 437-442 (2001).
46. + dendritic cells prolong the survival of vascularized heart allografts. J. Immunol. 168, 143-154 (2002).
47. + T cells can act as suppressor cells by affecting autologous dendritic cell conditioning and survival. J. Immunol. 168, 1060-1068 (2002).
48. Nakaseko, C. et al. Cytotoxic T lymphocyte antigen 4 (CTLA-4) engagement delivers an inhibitory signal through the membrane-proximal region in the absence of the tyrosine motif in the cytoplasmic tail. J. Exp. Med. 190, 765-774 (1999).
49. Mandelbrot, D. A. et al. Expression of B7 molecules in recipient, not donor, mice determines the survival of cardiac allografts. J. Immunol. 163, 3753-3757 (1999).
50. Chang, T. T., Jabs, C., Sobel, R. A., Kuchroo, V. K. and Sharpe, A. H. Studies in B7-deficient mice reveal a critical role for B7 costimulation in both induction and effector phases of experimental autoimmune encephalomyelitis. J. Exp. Med. 190, 733-740 (1999).
51. Dalton, D. K. et al. Multiple defects of immune cell function in mice with disrupted interferon-γ genes. Science 259, 1739-1742 (1993).
52. Fallarino, F. and Gajewski, T. F. Differentiation of antitumor CTL in vivo requires host expression of Stat1. J. Immunol. 163, 4109-4113 (1999).
53. Grohmann, U. et al. IL-12 acts directly on DC to promote nuclear localization of NF-κB and primes DC for IL-12 production. Immunitys 9, 315-323 (1998).